AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 1
Description: 75 mg oral tablet of prototype modified release (MR) 1
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 2
Description: 75 mg oral tablet of prototype MR 2
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 3
Description: 75 mg oral capsule of prototype MR 3
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 4
Description: 75 mg oral capsule of prototype MR 4
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 5
Description: 75 mg oral capsule of prototype MR 5
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 6
Description: 75 mg oral capsule of prototype MR 6
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 8
Description: 80 mg oral capsule of prototype MR 8
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 9
Description: 80 mg oral capsule of prototype MR 9
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 11
Description: 80 mg oral capsule of prototype MR 11
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 12
Description: 80 mg oral capsule of prototype MR 12
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 13
Description: 80 mg oral capsule of prototype MR 13
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 14
Description: 80 mg oral capsule of prototype MR 14
Study NCT02448433 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Phototherapy light-emitting glasses
Description: The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m\^2) upon awakening and progressive shift to earlier wake-up times.~Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.~During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls.
Study NCT00692731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: 500 mL/day of a beverage providing approximately 625 mg catechins
Description: Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
Study NCT00692731 — intervention group
Intervention type: OTHER
Intervention: Control beverage matched for energy and caffeine content
Description: 500 mL/day of a control beverage
Study NCT04057027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Description: During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.
Study NCT04057027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Milking
Description: Umbilical cord will be milked from th distance of 20cm from mother's side to the baby, for 3-4 times.
Study NCT01994967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
Study NCT01994967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
Study NCT02966808 — intervention group
Intervention type: BEHAVIORAL
Intervention: cognitive and behavioural questionnaires
Study NCT04548466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP bottle
Study NCT03499470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol for structured discharge and follow-up
Study NCT00960453 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods
Study NCT02826343 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xenon129 MRI imaging
Description: subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
Study NCT02826343 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gadolinium MRI
Description: subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
Study NCT02826343 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Advair (250mcg/50mcg) one puff twice a day
Description: subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
Study NCT03788759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Description: Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.
Study NCT03788759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Administration of placebo, as an adjunct to antipsychotic medication.
Study NCT03674580 — intervention group
Intervention type: BEHAVIORAL
Intervention: Follow-up of the suicidal patients
Description: No intervention. Follow-up of the suicidal patients
Study NCT00650884 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Ankle Dorsiflexion Dynasplint System
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
Study NCT00650884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Dorsiflexion Dynasplint System
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
Study NCT00650884 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ankle Dorsiflexion Dynasplint System
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
Study NCT03395262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active with caffeine
Description: Novel formula with caffeine
Study NCT03395262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active without caffeine
Description: Novel formula without caffeine
Study NCT03395262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose placebo
Study NCT03553199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRS, Tissue Retraction System
Description: Tissue Retraction System
Study NCT00956553 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervarix
Description: Three doses of Cervarix at month 0, 1 and 6.
Study NCT00956553 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Three doses of Gardasil at month 0, 1 and 6.
Study NCT01145209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01145209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT01145209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00124683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Study NCT00124683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal patch
Study NCT00124683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine transdermal patch
Study NCT01035645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation.
Study NCT02360033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systemic Therapy for Social Anxiety Disorder
Study NCT02360033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Social Anxiety Disorder
Study NCT00910039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
Study NCT00910039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
Study NCT01481987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epiretinal Membrane Surgical treatment
Description: epiretinal membrane peeling
Study NCT02550353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lenticule extraction
Description: Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
Study NCT02550353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femtosecond laser-assisted laser in situ keratomileusis
Description: track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
Study NCT01143870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Report Card
Description: Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade.
Study NCT01143870 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes Report Card
Description: Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade.
Study NCT02627417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone (Disulone®)
Description: Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
Study NCT02627417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone (Cortancyl®) alone followed by monitoring and standard of care
Description: Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
Study NCT02627417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (Cortancyl®)
Description: Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
Study NCT03435692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Plexus Catheter
Description: lumbar plexus catheter placed intraoperatively for perioperative pain control
Study NCT03435692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Epidural Catheter
Description: lumbar epidural catheter placed intraoperatively for perioperative pain control
Study NCT03435692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia
Description: Patient Controlled Analgesia (PCA) was started post operatively for perioperative pain control
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl was administered in the operating room for induction of anesthesia. Subsequent doses in the operating room were standardized to be given only for heart rate or blood pressure increases > 20% above baseline and occurring more than 30 minutes after the block if applicable.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intravenous fentanyl was administered in the operating room for induction of anesthesia. Subsequent doses in the operating room were standardized to be given only for heart rate or blood pressure increases > 20% above baseline and occurring more than 30 minutes after the block if applicable.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: In the operating room patients, intravenous morphine was administered if patients had a failed block and standardized to be given only for heart rate or blood pressure increases > 20% above baseline and after fentanyl had been administered. Intravenous Morphine was also administered in the operating room if the patient was randomized to the Patient Controlled Analgesia (PCA) arm of the study. Post operatively intravenous Morphine was administered as needed for severe pain.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: In the operating room patients, intravenous morphine was administered if patients had a failed block and standardized to be given only for heart rate or blood pressure increases > 20% above baseline and after fentanyl had been administered. Intravenous Morphine was also administered in the operating room if the patient was randomized to the Patient Controlled Analgesia (PCA) arm of the study. Post operatively intravenous Morphine was administered as needed for severe pain.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Intravenous Lorazepam was administered as needed for muscle spasm post operatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Intravenous Lorazepam was administered as needed for muscle spasm post operatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Intravenous Ondansetron was administered as needed for nausea and vomiting post operatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Intravenous Ondansetron was administered as needed for nausea and vomiting post operatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Intravenous Diphenhydramine was administered as needed for itching postoperatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Intravenous Diphenhydramine was administered as needed for itching postoperatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Oral Acetaminophen was administered as needed for pain in the Post-Anesthesia Care Unit (PACU) and then scheduled for 72 hours.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral Acetaminophen was administered as needed for pain in the Post-Anesthesia Care Unit (PACU) and then scheduled for 72 hours.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oral Oxycodone was administered as needed for breakthrough pain post operatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oral Oxycodone was administered as needed for breakthrough pain post operatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intravenous Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
Study NCT03435692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Intravenous Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
Study NCT01244529 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: galy A Plus
Description: galyfilcon A Plus, BC: 8.3 or 8.7
Study NCT01244529 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: seno A
Description: senofilcon A, BC:8.4 or 8.8
Study NCT01244529 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: galy A
Description: galyfilcon A , BC: 8.3 or 8.7
Study NCT04076787 — intervention group
Intervention type: DRUG
Intervention: Sunitinib
Description: patients who received sunitinib as first line therapy for mRCC
Study NCT01737424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126
Description: LC28-0126
Study NCT01737424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00969826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCPGC, Neulasta, Placebo
Description: A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
Study NCT01066429 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Dexamethasone and dose-dense immunochemoterapy
Description: Administration every 14 days of the EDOCH-R scheme.
Study NCT03446326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing
Description: Assess the non-invasively determined stroke volume and cardiac output response at different paced heart rates in patients with a cardiac pacemaker or implanted defibrillator with preserved ejection fractions (LVEF≥50%)
Study NCT03846180 — intervention group
Intervention type: DRUG
Intervention: Terlipressin
Description: Continuous or intermittent intravenous infusion of terlipressin was given.
Study NCT03846180 — intervention group
Intervention type: DRUG
Intervention: Somatostatin
Description: Continuous or intermittent intravenous infusion of somatostatin was given.
Study NCT03846180 — intervention group
Intervention type: DRUG
Intervention: Octreotide
Description: Continuous or intermittent intravenous infusion of octreotide was given.
Study NCT03859245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Photobiomodulation therapy, via Joovv red light/infrared LED device, three days/week, 20 minutes per session for experimental and control groups.
Study NCT03859245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation therapy, via Joovv red light/infrared LED device, three days/week, 20 minutes per session for experimental and control groups.
Study NCT03859245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Experimental group will follow a clinically prescribed ketogenic diet.